Patient Characteristics
| Characteristic | Data |
|---|---|
| Patients | 92 |
| Race | |
| White | 79 (85.9%) |
| Hispanic | 8 (8.7%) |
| Asian | 3 (3.3%) |
| Other | 2 (2.2%) |
| Age (y) | 69 (55–76) |
| Male | 55 (59.8%) |
| Primary site | |
| Skin | 74 (80.4%) |
| Other or unknown | 18 (19.6%) |
| BRAF V600 mutation | 24/91 (26.4%) |
| Brain metastasis | 26/91 (28.6%) |
| LDH level > normal | 15/92 (16.3%) |
| Immune checkpoint inhibitors | |
| Pembrolizumab (anti-PD-1 therapy) | 72 |
| Nivolumab (anti-PD-1 therapy) | 9 |
| Nivolumab and ipilimumab (anti-CTLA-4 therapy) | 10 |
| Nivolumab and relatlimab (anti-LAG-3 therapy) | 1 |
| Intervals (d) | |
| Baseline PET to therapy initiation | 33.5 (18–50) |
| Baseline PET and laboratory test | 22 (9–34.3) |
Qualitative data are number and percentage; continuous data are median and interquartile range.